jRCT2051260113招募中不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6) (VESPER-6)
未提供0 个研究点目标入组 954 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 954
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Aged >=18 years.
- •BMI of: >=30 kg/m2 or >=27.0 kg/m2 to <30.0 kg/m2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.
排除标准
- •Have a self-reported body weight change greater than 5% within 90 days prior to Screening.
- •Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.
- •History of acute or chronic pancreatitis.
- •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).
研究者
相似试验
招募中
不适用
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes (Enith2)OBESITY OR OVERWEIGHT AND TYPE 2 DIABETESjRCT20612500901,600
招募中
不适用
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema)*Atopic Dermatitis *Eczema, Atopic*Atopic Dermatitis
*Eczema, AtopicjRCT2031250615165
招募中
不适用
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older (BEETHOVEN)* Clostridioides Difficile Associated DiseasejRCT203126006632,000
已完成
1 期
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTSmetabolic bone diseases2023-503866-22-00Mesentech Inc.72
招募中
1 期
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-201 IN AMYOTROPHIC LATERAL SCLEROSISAmyotrophic lateral sclerosis2022-500758-41-00Quralis Corp.35